Radiogenomics: predicting clinical normal tissue radiosensitivity

Jan Alsner

Radiogenomics: predicting clinical normal tissue radiosensitivity

Publikation: Bidrag til bog/antologi/rapport/proceeding › Konferenceabstrakt i proceedings › Forskning

Abstract

Studies on the genetic basis of normal tissue radiosensitivity, or 'radiogenomics', aims at predicting clinical radiosensitivity and optimize treatment from individual genetic profiles. Several studies have now reported links between variations in certain genes related to the biological response to radiation injury and risk of normal tissue morbidity in cancer patients treated with radiotherapy. However, after these initial association studies including few genes, we are still far from being able to predict clinical radiosensitivity on an individual level. Recent data from our own studies on risk of subcutaneous fibrosis in breast cancer patients will be presented and discussed in relation to possible future studies in radiogenomics. One important and necessary basis for future studies is the collection of carefully designed clinical studies with the accrual of very large numbers of patients (the ESTRO GENEPI project)

Originalsprog	Engelsk
Titel	Radiother. Oncol.
Antal sider	1
Publikationsdato	2006
Udgave	81 (Suppl. 1)
Sider	S120
Status	Udgivet - 2006
Begivenhed	25th ESTRO Annual Meeting - Leipzig, Tyskland Varighed: 8 okt. 2006 → 12 okt. 2006

Konference

Konference	25th ESTRO Annual Meeting
Land/Område	Tyskland
By	Leipzig
Periode	08/10/2006 → 12/10/2006

OpenUrl tilgængelighed

Fuld tekst

Citationsformater

@inbook{856cee30084011dcbee902004c4f4f50,

title = "Radiogenomics: predicting clinical normal tissue radiosensitivity",

abstract = "Studies on the genetic basis of normal tissue radiosensitivity, or 'radiogenomics', aims at predicting clinical radiosensitivity and optimize treatment from individual genetic profiles. Several studies have now reported links between variations in certain genes related to the biological response to radiation injury and risk of normal tissue morbidity in cancer patients treated with radiotherapy. However, after these initial association studies including few genes, we are still far from being able to predict clinical radiosensitivity on an individual level. Recent data from our own studies on risk of subcutaneous fibrosis in breast cancer patients will be presented and discussed in relation to possible future studies in radiogenomics. One important and necessary basis for future studies is the collection of carefully designed clinical studies with the accrual of very large numbers of patients (the ESTRO GENEPI project)",

author = "Jan Alsner",

year = "2006",

language = "English",

pages = "S120",

booktitle = "Radiother. Oncol.",

edition = "81 (Suppl. 1)",

note = "25th ESTRO Annual Meeting ; Conference date: 08-10-2006 Through 12-10-2006",

}

TY - ABST

T1 - Radiogenomics: predicting clinical normal tissue radiosensitivity

AU - Alsner, Jan

PY - 2006

Y1 - 2006

N2 - Studies on the genetic basis of normal tissue radiosensitivity, or 'radiogenomics', aims at predicting clinical radiosensitivity and optimize treatment from individual genetic profiles. Several studies have now reported links between variations in certain genes related to the biological response to radiation injury and risk of normal tissue morbidity in cancer patients treated with radiotherapy. However, after these initial association studies including few genes, we are still far from being able to predict clinical radiosensitivity on an individual level. Recent data from our own studies on risk of subcutaneous fibrosis in breast cancer patients will be presented and discussed in relation to possible future studies in radiogenomics. One important and necessary basis for future studies is the collection of carefully designed clinical studies with the accrual of very large numbers of patients (the ESTRO GENEPI project)

AB - Studies on the genetic basis of normal tissue radiosensitivity, or 'radiogenomics', aims at predicting clinical radiosensitivity and optimize treatment from individual genetic profiles. Several studies have now reported links between variations in certain genes related to the biological response to radiation injury and risk of normal tissue morbidity in cancer patients treated with radiotherapy. However, after these initial association studies including few genes, we are still far from being able to predict clinical radiosensitivity on an individual level. Recent data from our own studies on risk of subcutaneous fibrosis in breast cancer patients will be presented and discussed in relation to possible future studies in radiogenomics. One important and necessary basis for future studies is the collection of carefully designed clinical studies with the accrual of very large numbers of patients (the ESTRO GENEPI project)

M3 - Conference abstract in proceedings

SP - S120

BT - Radiother. Oncol.

T2 - 25th ESTRO Annual Meeting

Y2 - 8 October 2006 through 12 October 2006

ER -

Radiogenomics: predicting clinical normal tissue radiosensitivity

Abstract

Konference

OpenUrl tilgængelighed

Fingeraftryk

Citationsformater